Are we closer to finding biomarkers for identifying acute drug-induced liver injury?
Are we closer to finding biomarkers for identifying acute drug-induced liver injury?
复制标题
我们是否更接近寻找识别急性药物性肝损伤的生物标志物？
作者：
D. Antoine;P. Lewis;C. Goldring;B. Park
近年来，已经有相当大的努力，以确定和开发新的生物标志物的急性药物性肝损伤（DILI）。很明显，迫切需要开发和鉴定敏感和特异的肝脏生物标志物，以定量评估临床前和临床研究之间的转换。新型生物标志物提供对导致临床DILI的基本机制的增强理解的潜力正日益得到认可。此外，非常需要能够在DILI的临床前模型和临床情况之间架起桥梁的机制生物标志物。因此，这些将使我们能够理解急性DILI预测模型的人类相关性以及对此类模型产生的数据的解释。这些生物标志物不仅可以加快药物开发的步伐，而且还可以提供即时检测，以便在新药获得许可后对患者和/或DILI特异性治疗进行分层。目前，具有一定临床实用性的推定生物标志物的数量很少，主要是因为与药物疗效相比，药物安全性科学受到的关注较少[1]。
Over recent years, there has been a considerable effort to identify and develop new biomarkers of acute drug-induced liver injury (DILI). It is clear that the development and qualification of sensitive and specific hepatic biomarkers that permit quantitative assessment of the translation between preclinical and clinical studies is urgently required. The potential for novel biomarkers to provide enhanced understanding of the fundamental mechanisms that result in clinical DILI is becoming increasingly recognized. Furthermore, there is a great need for mechanistic biomarkers that can bridge between preclinical models and the clinical situation of DILI. These will therefore enable us to understand the human relevance of predictive models of acute DILI and the interpretation of data generated from such models. Such biomarkers would not only accelerate the pace of drug development but also provide a point-of-care test to enable patient and/or DILI-specific treatment stratification once a new drug is licensed. Currently, the number of putative biomarkers that hold some clinical utility is low, mainly because less attention has been placed on the science of drug safety compared with drug efficacy [1].
影响因子：
15.9
作者：
McGill, Mitchell R.;Sharpe, Matthew R.;Jaeschke, Hartmut
通讯作者：
Jaeschke, Hartmut